Merjanova
eleonora.merjanova.wg12@
wharton.upenn.edu Duke University, Durham, NC B.S., Biology, B.A., Economics, 2006
Eleonora (Ella)
Philip S. Mishkin
philip.mishkin.wg12@wharton.upenn.edu University of Pennsylvania, Philadelphia, PA B.S.E., Summa Cum Laude, Chemical Engineering, 2006
Marc C. Montserrat
marc.montserrat.wg12@
wharton.upenn.edu ETSEIB, Barcelona, Spain Politecnico di Milano, Milan, Italy Fachhochshule Jena, Jena, Germany B.S. and M.S., Industrial Engineering, 2004
Investing or operating role of impact within the health and wellness industry.
Physic Ventures, San Francisco, CA Summer Associate, Summer 2011 Completed investment thesis and 30-page white paper on the future of healthy eating at home, focusing on digital media, social media, and consumer internet innovation. Collaborated daily with the Directors of U.S. Innovation for Unilever and PepsiCo, the two largest limited partners in Physic. .
Pro Mujer, New York, NY Associate, 2009-2010 Led international teams in review of microfinance operations for 5 Latin American countries; analysis resulted in strategic plan with goal to improve operational efficiency by 35% in 3 years.
Leerink Swann, New York, NY Senior Analyst, 2008-2009 Identified and analyzed strategic alternatives for clients; built valuation model, developed 60-page marketing document, and managed relationship between client and 12+ financial investors for leveraged buyout of $250M U.S. vaccines manufacturer.
Goldman Sachs, New York, NY Financial Analyst, 2006-2008 Analyzed domestic consumer trends and behavior as part of principal investing team for $1B securitized debt fund; led efforts to structure $3B in securitizations for domestic financial institutions.
An entrepreneurial opportunity within the biopharmaceutical sector, including business development, venture capital, or innovative start-ups.
Pfizer Inc., New York, NY Business Development Summer Associate, Summer 2011 Conducted evaluations for 6 potential global transactions including in-licenses, out-licenses and acquisi- tions spanning multiple stages of drug development and therapeutic areas. Led acquisition analysis of a private generics manufacturer and coordi- nated cross-functional team of R&D, Commercial, and Legal colleagues to frame and evaluate strategic and financial business case.
Deloitte Consulting, LLP, New York, NY and Philadelphia, PA Business Analyst / Consultant, 2006-2010 Led work-streams on multiple strategic engagements within the life sciences industry, executing projects across the value chain from R&D transforma- tional strategies to Sales & Marketing optimization. Developed and co- authored Massachusetts Biotechnology Council’s 2015 Strategic Report, which defined a strategic plan for Massachu- setts to maintain its global leadership position in biotechnology. Collabo- rated with the senior management team of a mid-tier pharmaceutical company to transform the Sales & Marketing organization; recom- mended and developed 35 initiatives across Sales, Marketing, and Managed Markets. Designed processes and supporting materials for a new R&D “collaboration model” at a global biopharmaceutical company.
An opportunity in an entrepreneurial organization to promote and deliver innovation in healthcare.
Genentech, South San Francisco, CA Interactive Marketing, Summer 2011 Led the creation of a framework to identify and quantify business opportunities in patient engagement, multicultural marketing and health literacy for pipeline and commercial- ized products. Recommendations to the interactive marketing team and a senior VP-level committee received enthusiastically.
Almirall, Barcelona, Spain Corporate Project Manager, 2008-2010 Managed a global team of 40 mem- bers from 11 affiliates and partners in 4 continents responsible for a portfolio of 43 products, growing sales from €9M in 2007 to €90M in 2010 repre- senting 66% of growth in company. Post-M&A integration responsibilities, working 25% of the time in Germany.
Siemens VDO, Rubi, Spain Project Manager, 2006-2008 Led international team of 19 members, managing 5 projects (€25M annual sales, 25% of plant turnover). Achieved safe launch of 30 products, including a project in 33% of standard lead-time, introduced 2 new technolo- gies, and created a new assembly line concept. Achieved business acquisition of 3 projects (€90M revenue).
Altran, Barcelona, Spain Consultant, 2004-2006 Achieved €€3.4M savings in process optimization, actively participated in ramp-up of a new business unit including candidate interviews, project prospection and offer preparation, and developed 3 new customers.
20
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40